Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

significant proportion of infected individuals, leading to cirrhosis, primary liver cancer, and even death.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The Company's primary focus is rapid progress toward the commercialization of its two lead compounds, Albuferon(R) for hepatitis C, and LymphoStat-B(R) for lupus. Phase 3 clinical trials of both compounds are now underway.

In June 2006, HGS announced that the U.S. Government exercised its option under an existing contract to purchase 20,000 doses of ABthrax(TM) for the treatment of anthrax disease. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of hematopoietic and solid malignancies, in addition to an antibody to the CCR5 receptor for the treatment of HIV/AIDS.

For more information about HGS, please visit the Company's web site at www.hgsi.com. For more information about Albuferon, please visit http://www.hgsi.com/products/albuferon.html. Health professionals or patients interested in Albuferon clinical trials or other studies involving HGS products may inquire via the Contact Us section of the Company's web site, www.hgsi.com/products/request.html, or by calling us at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:8/4/2015)... -- Among 1,000 U.S. consumers, the majority (65.3 percent) ... surveyed are aware of prescription savings cards, and just ... to findings from a new survey released today by ... improving the health and well-being of individuals, families and ... and women, ages 21 and older, on their spending, ...
(Date:8/4/2015)... Wis. , Aug. 4, 2015  Ironshore ... agreement with Restore Health, a company specializing in ... a double-blind clinical trial, designed to evaluate the ... in development to treat Attention-deficit/hyperactivity disorder (ADHD). This ... Restore Health originally partnered with Ironshore ...
(Date:8/3/2015)... 2015  Landauer, Inc. (NYSE: LDR ), a ... monitoring, outsourced medical physics services and high quality medical ... for the fiscal third quarter 2015 after the market ... The Company will also host a conference call for ... Central Time (10:00 a.m. Eastern Time). Investors may access ...
Breaking Medicine Technology:New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2
... 2011 NeoStem, Inc., (NYSE-Amex: NBS ) ... its common stock and warrants in an underwritten public offering. All ... by NeoStem. The offering is subject to market conditions, and there ... may be completed, or as to the actual size or terms ...
... 2011 In an effort to expand its offerings ... and outpatient markets, with an initial focus on home ... an exclusive alliance with CME America to distribute the ... (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO) The five-year exclusive distribution agreement ...
Cached Medicine Technology:NeoStem Announces Proposed Public Offering of Common Stock 2NeoStem Announces Proposed Public Offering of Common Stock 3B. Braun and CME America Partner to Provide BodyGuard® Infusion Pumps 2B. Braun and CME America Partner to Provide BodyGuard® Infusion Pumps 3
(Date:8/4/2015)... New York, NY (PRWEB) , ... August 04, ... ... in a vegetarian capsule formula. Healthy Origins® Cognizin® is a trademark for ... a preferred base for a capsule for those applications which have more of ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s hard to ... & Day Spa in Santa Barbara, CA is offering the solution by offering ... permanently eliminates sweat and odor glands in the underarms. This simple and permanent ...
(Date:8/4/2015)... ... August 04, 2015 , ... Recent studies ... shown a rise in binge drinking among certain populations and specific ... are continuing to examine trends and evidence to help facilitate health care treatment ...
(Date:8/4/2015)... , ... August 04, 2015 , ... They say a ... understand certain health conditions, pictures and medical art can be essential. StayWell, a health ... , Krames Patient Education solutions have been used by physicians and other health ...
(Date:8/4/2015)... ... August 04, 2015 , ... SanusEO, the healthcare industry ... its executive leadership team as Senior Vice President of Sales and Marketing. Mr. ... expanding global markets with a special emphasis on the healthcare industry. , Today, ...
Breaking Medicine News(10 mins):Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3
... With guidance from a specialized scan, radiation oncologists at ... percent the number of lymph nodes critical for removing ... VIDEO ALERT: Additional audio and video resources, ... and other researchers presenting at San Antonio Breast Cancer ...
... American Institute of Ultrasound in Medicine (AIUM) recently ... Ultrasound on November 8 in Orlando, Florida. ... of the ultrasound community, drawing representatives from 46 ... issues related to emerging point-of-care ultrasound technologies. ...
... cancer and bone metastases, denosumab delayed skeletal-related side effects ... according to results presented at the 33rd Annual CTRC-AACR ... "The average life expectancy of patients with metastatic ... can prolong the time without a skeletal-related event by ...
... It,s a medical Catch-22: carotid artery surgery can itself cause ... UT Southwestern Medical Center researchers have now developed a ... and health history to assess the danger the surgery poses, ... fully informed choice about whether to have the procedure. ...
... FRIDAY, Dec. 10 (HealthDay News) -- Human milk has long ... some breast-feeding experts and advocates disagree whether breast-milk banks -- ... Drug Administration -- should remain unregulated or whether lactating mothers ... An FDA panel of experts said earlier this week ...
... radiologist at Boston Medical Center (BMC) and a professor ... is the recipient of the 2010 Marie Sklodowska-Curie Award ... which is presented annually to an individual who has ... was given to Kuligowska during the Association,s annual business ...
Cached Medicine News:Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 3Health News:AIUM spearheads collaboration to develop guidelines for point-of-care ultrasound applications 2Health News:Denosumab delayed time to first skeletal-related side effect 2Health News:Researchers establish new rule to predict risk of stroke, death from surgery that prevents it 2Health News:Researchers establish new rule to predict risk of stroke, death from surgery that prevents it 3Health News:FDA Weighs In as Sharing of Breast Milk Booms 2Health News:FDA Weighs In as Sharing of Breast Milk Booms 3Health News:BMC radiologist receives 2010 Marie Sklodowska-Curie Award from AAWR 2
... The PANBIO Inc. Indirect Fluorescence ... (ANA) HEp2 is intended for the ... (Immunoglobulin G) antinuclear antibodies in human ... can be used as an aid ...
Anti-Tg and Anti-TPO are two major autoantibodies implicated in autoimmune related thyroiditis and aid in the differential diagnosis of Hashimoto's thyroiditis and Graves' disease....
... the medication most commonly prescribed for the prevention ... attacks and strokes. However, a number of studies ... people taking daily aspirin therapy to prevent a ... full benefits. These people are at greater ...
... system provides both pressure and flow ... or in a combined screen format ... and Volcano's unique Doppler FloWire. Physiologic ... tools to assess ambiguous or intermediate ...
Medicine Products: